Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Atypical antipsychotic

or Classic Psychedelic

or Stimulant

Use the filters below to narrow your results.

Other values:

None (111) · Benzedrex (1) · Caplyta (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Rexulti (1) · Vraylar (1)

5-HT2A agonist (26) · Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Contains LSA (2) · Contains mescaline (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)

Other values:

None (113) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)

None (113) · 42 mg PO once daily with food (no titration) (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (113) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · 42 mg capsules (1)

None (113) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 42 mg/d (1) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1)

None (112) · Oral (4)

None (112) · 30–60 minutes (1) · Antipsychotic effect over weeks (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Weeks for psychosis/mood efficacy (1)

None (112) · 8–12 hours (1) · Daily dosing (2) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

None (112) · 3–5 hours (1) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · ~18 hours (terminal) (1) · ~91 hours (1)

None (112) · 70–90% (oral) (1) · Adequate oral bioavailability (1) · Limited but adequate; take with food (1) · ~95% (1)

None (112) · Limited data (1) · Limited data; National Pregnancy Registry available (1) · Limited data; National Pregnancy Registry for Atypical Antipsychotics (1) · Not established (1)

None (112) · Rx (3) · Schedule I (United States) (1)

Showing below up to 116 results in range #1 to #116.

1

2

3

4

5

A

B

C

D

E

H

I

Isopropylphenidate

L

M

N

P

R

RTI-111

S

San Pedro cactus

T

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"